SREBF1 and metabolic syndrome: Recent studies have proposed a potential link between the PI3K/AKT pathway and dyslipidemia, and PI3K/AKT activation enhances SREBP-1 activity, further regulating the enzymes involved in the synthesis of cholesterol and TG in the liver and other tissues, which leads to dyslipidemia (53).